M&A Deal Summary |
|
---|---|
Date | 2020-10-23 |
Target | Clinical Laboratory Improvement Amendments |
Sector | Life Science |
Buyer(s) | ProPhase Labs |
Deal Type | Add-on Acquisition |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1989 |
Sector | Life Science |
Employees | 113 |
Revenue | 44M USD (2023) |
ProPhase Labs is a diversified natural health medical science company. It develops and markets clinically proven remedies including the highly effective Cold-EEZE® and Kids-EEZE® product lines. ProPhase Labs was founded in 1989 and is based in Garden City, New York.
DEAL STATS | # |
---|---|
Overall | 1 of 2 |
Sector (Life Science) | 1 of 2 |
Type (Add-on Acquisition) | 1 of 2 |
State (New Jersey) | 1 of 1 |
Country (United States) | 1 of 2 |
Year (2020) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2017-01-09 |
Cold-EEZE
Doylestown, Pennsylvania, United States Cold-EEZE is a cold remedy zinc gluconate lozenges are clinically proven to significantly reduce the duration of the common cold. |
Sell | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2021-08-11 |
Nebula Genomics
San Francisco, California, United States Nebula Genomics provides consumers access to affordable and secure whole-genome sequencing via its online portal. Nebula’s solution is powered by the innovations of George Church, Ph.D. Dr. Church has pioneered the development of multiple DNA sequencing methods, including molecular multiplexing approaches that enable next-generation DNA sequencing (NGS) as well as nanopore sequencing. Nebula Genomics was founded in 2016 and is based in San Francisco, California. |
Buy | $15M |